TY - JOUR
T1 - Clinical use of an antiprolactinaemic drug
T2 - Dihydroergocristine
AU - Scarduelli, C.
AU - Cavioni, V.
AU - Galparoli, C.
AU - Spellecchia, D.
AU - Crosignani, P. G.
AU - Ferrari, C.
PY - 1987
Y1 - 1987
N2 - Dihydroergocristine. 20-40 mg/day, reduced serum prolactin to normal in h out of 40 hyperprolactinaemic women and by 50 per cent in a further 7 women. Menstruation was restored in 19 out of 29 of the women with amenorrhoea. and ovulation occurred in 21 of the 40 patients. When given to puerperal women, 20 mg/ day for 10 days. dihydroergocristine prevented lactation without untoward side effects. Dopaminergic drugs have become the standard treatment for hyperprolactinaemic disorders and also for the prevention of puerperal lactation (Thor-ner et al., 1980). Bromocriptine and other potent dopaminergic drugs, though very effective, are occasionally not tolerated by individual patients, and the need for alternative drugs has arisen. Dihydroergocristine, a well tolerated vasoactive drug which has been used for many years in the treatment of vascular disorders, has recently been shown to possess a prolac-tin lowering effect in acute studies (Ferrari el al., 1983). The present work was to investigate the possible clinical use of dihydroergocristine as an antiprolactinaemic agent
AB - Dihydroergocristine. 20-40 mg/day, reduced serum prolactin to normal in h out of 40 hyperprolactinaemic women and by 50 per cent in a further 7 women. Menstruation was restored in 19 out of 29 of the women with amenorrhoea. and ovulation occurred in 21 of the 40 patients. When given to puerperal women, 20 mg/ day for 10 days. dihydroergocristine prevented lactation without untoward side effects. Dopaminergic drugs have become the standard treatment for hyperprolactinaemic disorders and also for the prevention of puerperal lactation (Thor-ner et al., 1980). Bromocriptine and other potent dopaminergic drugs, though very effective, are occasionally not tolerated by individual patients, and the need for alternative drugs has arisen. Dihydroergocristine, a well tolerated vasoactive drug which has been used for many years in the treatment of vascular disorders, has recently been shown to possess a prolac-tin lowering effect in acute studies (Ferrari el al., 1983). The present work was to investigate the possible clinical use of dihydroergocristine as an antiprolactinaemic agent
UR - http://www.scopus.com/inward/record.url?scp=0023098110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023098110&partnerID=8YFLogxK
U2 - 10.3109/01443618709068524
DO - 10.3109/01443618709068524
M3 - Article
AN - SCOPUS:0023098110
VL - 7
SP - 225
EP - 227
JO - Journal of Obstetrics and Gynaecology
JF - Journal of Obstetrics and Gynaecology
SN - 0144-3615
IS - 4
ER -